Research programme: human cytomegalovirus inhibitors - BayerAlternative Names: Human cytomegalovirus inhibitors research programme - Bayer
Latest Information Update: 08 Nov 2006
At a glance
- Originator Bayer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 08 Nov 2006 No development reported - Preclinical for Cytomegalovirus infections treatment in Germany (unspecified route)
- 06 Mar 2002 Preclinical trials in Cytomegalovirus infections in Germany